NCT04616586 - SILtuximab in Viral ARds (SILVAR) Study | Biotech Hunter

Enrollment

555

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions

Acute Respiratory Distress SyndromeLung DiseasesPneumoniaRespiratory Tract InfectionsRespiratory Tract Disease

Interventions

DRUG

Siltuximab

11 mg/kg IV administered over 1 hour

OTHER

Normal Saline

IV administered over 1 hour

Trial Locations (2)

Atrium Health, Charlotte

Sparrow Clinical Research Institute, Lansing